Raptor’s mission is to research, produce and deliver medicines that improve life for patients with severe, rare diseases. Raptor’s lead assets, RP103 and RP104, are proprietary delayed-release forms of cysteamine being developed for treatment of nephropathic cystinosis (NDA and MAA filed), Huntington’s disease (Phase 2/3), and non-alcoholic steatohepatitis (Phase 2b).
- Sector: Healthcare
- Status: Public (NASDAQ: RPTP)
- Geographic Market: U.S.
- Investment Year: 2011
- Investment Team: Ashley Friedman, Yuriy Prilutskiy
Visit the company’s website.
